SJS Investment Consulting
FHTX icon

SJS Investment Consulting’s Foghorn Therapeutics FHTX Stock Holding History

SJS Investment Consulting’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$365 Buy
102
+93
+1,033% +$490 ﹤0.01% 2817
2026
Q2 		$44 Buy
+9
New +$40 ﹤0.01% 2750

Other funds holding FHTX

China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
GF Fund Management
GF Fund Management Guangzhou, China $7.72B AUM 122.96% 1-Year Est. Return
Sterling Capital Management
Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return
TD Waterhouse Canada
TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
TFC Financial Management
TFC Financial Management Boston, Massachusetts $893M AUM 15.25% 1-Year Est. Return
North Star Investment Management
North Star Investment Management Chicago, Illinois $1.85B AUM 21.53% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
Essential Partners
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

SJS Investment Consulting's FHTX Position: Q3 2026 in Review

SJS Investment Consulting increased its Foghorn Therapeutics (FHTX) stake by 1,033% in Q3 2026, buying an estimated $490 and bringing the position to 102 shares worth $365. The position accounts for ﹤0.01% of the portfolio, ranked #2817.

SJS Investment Consulting first reported a position in FHTX in Q2 2026 and has held it in 2 quarters since. 14 funds tracked by Wall St. Rank hold FHTX as of Q3 2026.

  • SJS Investment Consulting held 102 shares of Foghorn Therapeutics worth $365 as of Q3 2026.
  • SJS Investment Consulting bought 93 Foghorn Therapeutics shares in Q3 2026, an estimated $490.
  • Foghorn Therapeutics made up ﹤0.01% of SJS Investment Consulting's portfolio in Q3 2026, its #2817 holding.
  • SJS Investment Consulting first reported a position in Foghorn Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • 14 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q3 2026.

Based on SJS Investment Consulting's 13F filing for Q3 2026, filed 26 Oct 2026.